In humans, the first data regarding the beneficial effects of SGLT-2 inhibitors on HF were published in 2015 by Zinman et al. In particular, in the EMPAREG OUTCOME Study, which enrolled 7020 patients with T2DM and increased CVD risk, empagliflozin was superior to a placebo with regard to hospitalization rates due to HF, as well as deaths from CVD causes [31]. Here, SLC5A2 is linked to type 2 diabetes mellitus.